[NH:1]1[CH2:6][CH2:5][CH:4]([C:7]2[C:15]3[C:10](=[CH:11][CH:12]=[CH:13][CH:14]=3)[NH:9][CH:8]=2)[CH2:3][CH2:2]1.[CH3:16][O:17][C:18](=[O:28])[C:19]1[CH:24]=[CH:23][C:22]([Br:25])=[C:21]([CH2:26]Br)[CH:20]=1>>[CH3:16][O:17][C:18](=[O:28])[C:19]1[CH:24]=[CH:23][C:22]([Br:25])=[C:21]([CH2:26][N:1]2[CH2:6][CH2:5][CH:4]([C:7]3[C:15]4[C:10](=[CH:11][CH:12]=[CH:13][CH:14]=4)[NH:9][CH:8]=3)[CH2:3][CH2:2]2)[CH:20]=1This compound was prepared following the procedure described in example 1 (part D) starting with 0.2 g (1 mmol) of 3-piperidin-4-yl-1H-indole and 0.39 g (1.3 mmol) 4-bromo-3-bromomethyl-benzoic acid methyl ester. After ionic exchange purification, 0.196 g (46% of yield) of 4-bromo-3-[4-(1H-indol-3-yl)-piperidin-1-ylmethyl]-benzoic acid methyl ester were obtained.